OneSource Specialty Pharma Limited (NSE:ONESOURCE)
India · Delayed Price · Currency is INR | Market Cap | 185.67B -9.5% |
| Revenue (ttm) | 16.86B +10.8% |
| Net Income | -16.21M |
| EPS | -0.14 |
| Shares Out | 114.67M |
| PE Ratio | n/a |
| Forward PE | 25.32 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 277,518 |
| Open | 1,583.10 |
| Previous Close | 1,581.70 |
| Day's Range | 1,577.10 - 1,634.50 |
| 52-Week Range | 1,057.00 - 1,917.80 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 2,078.25 (+28.36%) |
| Earnings Date | Oct 27, 2026 |
About NSE:ONESOURCE
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Singapore, the United States, Spain, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of pre-clinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fix... [Read more]
Financial Performance
In fiscal year 2026, NSE:ONESOURCE's revenue was 14.23 billion, a decrease of -1.49% compared to the previous year's 14.45 billion. Losses were -738.03 million, 310.7% more than in 2025.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ONESOURCE stock is "Strong Buy." The 12-month stock price target is ₹2,078, which is an increase of 28.36% from the latest price.
News
OneSource Specialty Pharma Transcript: Q2 26/27
Q2 revenue and EBITDA grew strongly, with margin expansion as new DDC capacity came online. FY 2028 guidance was reaffirmed, while line qualification, shipping delays and working-capital timing remain key execution factors.
OneSource Specialty Pharma Quarterly report: Q2 2027
OneSource Specialty Pharma has published its Q2 2027 quarterly earnings report on October 27, 2026.
OneSource Specialty Pharma Slides: Q2 2027
OneSource Specialty Pharma has posted slides in relation to its Q2 2027 quarterly earnings report, which was published on October 27, 2026.
OneSource Specialty Pharma Transcript: Q1 26/27
Q1 FY 2027 saw 37% revenue and 39% EBITDA growth year-over-year, driven by semaglutide launches, new contracts, and capacity expansions. The company reaffirmed FY 2028 guidance and expects continued growth from biologics, drug device, and soft gelatin segments.
OneSource Specialty Pharma Quarterly report: Q1 2027
OneSource Specialty Pharma has published its Q1 2027 quarterly earnings report on July 25, 2026.
OneSource Specialty Pharma Slides: Q1 2027
OneSource Specialty Pharma has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on July 25, 2026.
OneSource Specialty Pharma Transcript: Q4 25/26
Q4 FY 2026 saw a strong sequential recovery with 47% revenue growth, driven by semaglutide launches and capacity expansion. The company reaffirmed its FY 2028 guidance of $400 million revenue and 40% EBITDA margin, with robust demand and new approvals supporting future growth.
OneSource Specialty Pharma Slides: Q4 2026
OneSource Specialty Pharma has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 13, 2026.
OneSource Specialty Pharma Quarterly report: Q4 2026
OneSource Specialty Pharma has published its Q4 2026 quarterly earnings report on May 13, 2026.
OneSource Specialty Pharma Annual report: Q4 2026
OneSource Specialty Pharma has published its Q4 2026 annual report on May 13, 2026.
OneSource Specialty Pharma Transcript: Q3 25/26
Q3 FY 2026 saw a 26% revenue decline due to regulatory delays in Canada, impacting EBITDA and PAT. Despite near-term softness, robust demand, capacity expansion, and strong customer partnerships support confidence in achieving FY 2028 guidance of $400M revenue and $160M EBITDA.
OneSource Specialty Pharma Slides: Q3 2026
OneSource Specialty Pharma has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on January 23, 2026.
OneSource Specialty Pharma Quarterly report: Q3 2026
OneSource Specialty Pharma has published its Q3 2026 quarterly earnings report on January 23, 2026.
OneSource Specialty Pharma Transcript: Q2 25/26
Q2 and H1 FY2026 saw strong revenue and EBITDA growth, driven by robust demand and successful capacity expansion. The company reiterated its FY2028 revenue outlook of $500 million, with significant launches expected from March and ongoing investments in capacity and acquisitions.
OneSource Specialty Pharma Slides: Q2 2026
OneSource Specialty Pharma has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 11, 2025.
OneSource Specialty Pharma Quarterly report: Q2 2026
OneSource Specialty Pharma has published its Q2 2026 quarterly earnings report on November 11, 2025.